Xbrane Biopharma AB
Xbrane Biopharma AB, a pioneering biotechnology company headquartered in Sweden, focuses on the development of innovative biosimilars and biologics. Founded in 2006, Xbrane has made significant strides in the biopharmaceutical industry, particularly in the fields of ophthalmology and oncology. The company is renowned for its flagship product, Xlucane, a biosimilar to Lucentis, which addresses serious eye diseases and showcases Xbrane's commitment to enhancing patient care through affordable treatment options. With a strong presence in Europe and expanding operations globally, Xbrane Biopharma has established itself as a key player in the biosimilar market, recognised for its rigorous development processes and high-quality standards. As Xbrane continues to advance its pipeline, it remains dedicated to delivering innovative solutions that meet the evolving needs of healthcare providers and patients alike.
DitchCarbon Score
How does Xbrane Biopharma AB's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Xbrane Biopharma AB's score of 16 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Xbrane Biopharma AB's reported carbon emissions
In 2022 and 2023, Xbrane Biopharma AB reported carbon emissions of approximately 9,000 kg CO2e for Scope 2, with no emissions recorded for Scope 1. This consistent figure indicates a stable energy consumption pattern, primarily related to indirect emissions from purchased electricity. Currently, Xbrane Biopharma AB has not set specific reduction targets or initiatives, nor have they made any climate pledges. This lack of formal commitments suggests that the company may be in the early stages of developing a comprehensive climate strategy. As a biopharmaceutical company headquartered in Sweden, Xbrane operates within an industry increasingly focused on sustainability and carbon footprint reduction. The absence of significant emissions reductions or targets highlights an opportunity for the company to enhance its environmental commitments in alignment with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | 9,000 | 0,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Xbrane Biopharma AB is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
